Fuzionaire Diagnostics, Inc. (“Fuzionaire Dx”) today announced a collaborative research agreement with McGill University (“McGill”) and The Neuro (Montreal Neurological Institute-Hospital). The collaboration will combine Fuzionaire Dx’s radiopharmaceutical discovery platform and the world-class nuclear medicine and clinical imaging capabilities at McGill and The Neuro to develop new ways to detect and treat neurodegenerative diseases.
Fuzionaire Dx’s versatile chemistry-driven platform, which can radiofluorinate molecules in seconds and at ambient temperature, has the potential to generate a wide variety of novel radiopharmaceuticals enabling clinicians to better diagnose and treat cancers, tissue damage, and cardiovascular and neurodegenerative diseases
To read more please visit:
https://apnews.com/Business%2520Wire/d9f703132903473989ab0203395b8d7b
Source: AP News